Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orpheris, Inc.
Redwood City, California, United Statesorpheris.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Orpheris has completed Phase 1 studies of OP-101 and enrolled patients in a Phase 2 PRANA clinical study for severe COVID-19. The company received FDA Orphan Drug Designation for OP-101 for childhood cerebral adrenoleukodystrophy (ccALD).
- Therapeutic areas
- PsychiatryRare DiseasesNeurologyInfectious Diseases
- Modalities
- Small molecule drugChemical drugsHydroxyl dendrimer therapeutics
- Industry
- Biotech
Beyond the preview
Go deeper on Orpheris, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orpheris, Inc..